About this item:

33 Views | 10 Downloads

Author Notes:

Dr. Stefan M Pulst, 175 North Medical Drive East, Salt Lake City, UT 84132, USA, Tel: (801)585-7575, stefan.pulst@hsc.utah.edu.

Dr. Sheng-Han Kuo, 650 West 168th Street, Room 305, New York, NY 10032, USA. Tel: (212) 342-3753, Fax: (212) 305-1304, sk3295@columbia.edu.

Ms. Figueroa: study concept and design, statistical analysis and interpretation, writing the manuscript, critical revision of the manuscript for important intellectual content.

Dr. Gan: study concept and design, statistical analysis and interpretation, critical revision of the manuscript for important intellectual content.

Drs. Perlman, Wilmot, Gomez, Schmahmann, Paulson, Shakkottai, Ying, Zesiewicz, Bushara, Geschwind, and Xia: acquisition of data.

Dr. Subramony: study concept and design, acquisition of data, study supervision.

Drs. Ashizawa and Pulst: study concept and design, acquisition of data, critical revision of the manuscript for important intellectual content, study supervision.

Dr. Kuo: study concept and design, acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content.

Dr. Zesiewicz has served as a clinical advisor for Steminent Biotherapeutics, and she has received travel reimbursement from the department of neurology at University of Southern Florida; has received travel reimbursement for a Biohaven Pharmaceuticals meeting. Dr. Zesiewicz has served on the editorial board for Neurodegenerative Disease Management and Tremor and other Hyperkinetic Movements, and has received research support for her division for approximately 20 clinical trials for Parkinson’s disease, Friedreich’s ataxia, and spinocerebellar ataxias. Dr. Zesiewicz’s division is a site in a multi-site trial of Parkinson’s disease patients with the LRRK2 mutation and is sponsored by the National Institutes of Health but funded by Emory University.

The rest of authors report no conflicts of interest.

Subjects:

Research Funding:

The CRC-SCA natural history study is supported by the Rare Disease Clinical Research Network (RDCRN) (RC1NS068897), and the National Ataxia Foundation.

Dr. Stefan Pulst is supported by NIH/NINDS RC4NS073009, R01NS033123, R37NS033123.

Dr. Kuo is supported by the NINDS K08 NS083738, Louis V. Gerstner Jr. Scholarship, American Brain Research Training Fellowship, Parkinson Disease Foundation, American Parkinson’s Disease Association, Rare Disease Clinical Research Network (RDCRN) (RC1NS068897), International Essential Tremor Foundation, and NIEHS pilot grant ES009089, the Smart Foundation.

Dr. Gan is supported by the National Natural Science Foundation of China (U1505222).

Keywords:

  • repeat expansions
  • neurodegeneration
  • C9ORF72
  • amyotrophic lateral sclerosis
  • frontotemporal dementia
  • ATXN2
  • Spinocerebellar ataxia
  • ataxia
  • genetic modifier
  • disease progression

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias

Show all authors Show less authors

Journal Title:

Movement Disorders

Volume:

Volume 33, Number 3

Publisher:

, Pages 497-498

Type of Work:

Article | Post-print: After Peer Review

Abstract:

N/A

Copyright information:

© 2017 International Parkinson and Movement Disorder Society

Export to EndNote